United Therapeutics chairperson & CEO Martine Rothblatt sells $5.2m in stock

Martine Rothblatt, Chair and CEO of United Therapeutics, sold a substantial $5.2 million worth of shares on October 7, 2026, according to a SEC filing. The sale comprised 9,400 shares of the company's common stock, bought and sold under a pre-set 10b5-1 trading plan. Prior to these sales, Rothblatt used her stock options to purchase 9,500 shares at $117.76 each, amounting to $1,118,720.

These option-related transactions were also governed by the same 10b5-1 plan, which is set to remain in effect until either the exercise of 1,734,410 stock options expiring on March 15, 2027, or December 31, 2026. Post these transactions, Rothblatt now holds 324,443 shares indirectly through multiple family trusts. United Therapeutics, with a market cap of $22.85 billion, currently trades at $532.78 per share, according to InvestingPro analysis.

The stock has been flagged as potentially overvalued. United Therapeutics' second-quarter 2026 earnings reported an EPS of $7.27, beating the estimated $7.09 per share, while revenue fell short of expectations at $783.3 million compared to the forecasted $807.05 million. Following this, BofA Securities lowered its price target from $613 to $559, maintaining a Neutral rating, citing a 2.9% revenue miss and the company's decision to no longer affirm its Tyvaso sales guidance.

The patent win for United Therapeutics' Tyvaso in a recent legal battle boosted Cantor Fitzgerald's rating to Overweight with a $700 target, while BTIG upgraded the stock to Buy with a $728 target. Meanwhile, Goldman Sachs maintained a Sell rating with a $321 target, citing concerns over a declining base business despite the current valuation.